Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Pharmacotherapy of Hypertension in Chronic Dialysis Patients.

Georgianos PI, Agarwal R.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2062-2075. Epub 2016 Oct 24.

PMID:
27797886
2.

Left ventricular dysfunction in the haemodialysis population.

Sood MM, Pauly RP, Rigatto C, Komenda P.

NDT Plus. 2008 Aug;1(4):199-205. doi: 10.1093/ndtplus/sfn074.

3.

Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

Charytan D.

Curr Opin Nephrol Hypertens. 2014 Nov;23(6):578-85. doi: 10.1097/MNH.0000000000000067. Review.

4.

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis.

Morishita Y, Kusano E, Nagata D.

Open Cardiovasc Med J. 2014 Feb 7;8:6-11. doi: 10.2174/1874192401408010006. eCollection 2014.

5.

Pharmacologic management of chronic reno-cardiac syndrome.

Hawwa N, Schreiber MJ Jr, Tang WH.

Curr Heart Fail Rep. 2013 Mar;10(1):54-62. doi: 10.1007/s11897-012-0122-8. Review.

6.

Can losartan and blood pressure control peri arteriovenous fistula creation ameliorate the early associated left ventricular hypertrophic response a randomised placebo controlled trial.

Zentner D, Pedagogos E, Yapanis A, Karapanagiotidis S, Kinghorn A, Alexiou A, Lee G, Raspudic M, Aggarwal A.

BMC Res Notes. 2012 May 29;5:260. doi: 10.1186/1756-0500-5-260.

7.

Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients.

Morishita Y, Watanabe M, Hanawa S, Iimura O, Tsunematsu S, Ishibashi K, Kusano E.

Int J Nephrol Renovasc Dis. 2012;5:45-51. doi: 10.2147/IJNRD.S30203. Epub 2012 Mar 21.

8.

Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.

Powers BJ, Coeytaux RR, Dolor RJ, Hasselblad V, Patel UD, Yancy WS Jr, Gray RN, Irvine RJ, Kendrick AS, Sanders GD.

J Gen Intern Med. 2012 Jun;27(6):716-29. doi: 10.1007/s11606-011-1938-8. Epub 2011 Dec 7. Review.

9.

Antihypertensive agents in hemodialysis patients: a current perspective.

Inrig JK.

Semin Dial. 2010 May-Jun;23(3):290-7. doi: 10.1111/j.1525-139X.2009.00697.x. Epub 2010 Mar 29. Review.

10.

Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis.

Tai DJ, Lim TW, James MT, Manns BJ, Tonelli M, Hemmelgarn BR; Alberta Kidney Disease Network.

Clin J Am Soc Nephrol. 2010 Apr;5(4):623-30. doi: 10.2215/CJN.07831109. Epub 2010 Feb 4. Review.

11.

Decreased pulse pressure during hemodialysis is associated with improved 6-month outcomes.

Inrig JK, Patel UD, Toto RD, Reddan DN, Himmelfarb J, Lindsay RM, Stivelman J, Winchester JF, Szczech LA.

Kidney Int. 2009 Nov;76(10):1098-107. doi: 10.1038/ki.2009.340. Epub 2009 Sep 2.

Supplemental Content

Support Center